Potential mechanism of thymosin-α1-membrane interactions leading to pleiotropy: experimental evidence and hypotheses

References

• Goldstein AL, Guha A, Zatz MM, et al. Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci U S A. 1972;69:1800–1803.
   PubMed Web of Science ®Google Scholar
• Low TL, Thurman GB, McAdoo M, et al. The chemistry and biology of thymosins. I. Isolation, characterization, and biological activities of thymosin alpha1 and polypeptide beTα1 from calf thymus. J Biol Chem. 1979;254:981–986.
   PubMed Web of Science ®Google Scholar
• T L L, Goldstein AL. The chemistry and biology of thymosin. II. Amino acid sequence analysis of thymosin alpha1 and polypeptide beTα1. J Biol Chem. 1979;254:987–995.
   PubMed Web of Science ®Google Scholar
• Goldstein AL, Hannappel E, Sosne G, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12:37–51.
   PubMed Web of Science ®Google Scholar
• Kleinman HK, Sosne G. Thymosin β4 promotes dermal healing. Vitam Horm. 2016;102:251–275.
   PubMed Web of Science ®Google Scholar
• Marks ED, Kumar A. Thymosin β4: roles in development, repair, and engineering of the cardiovascular system. Vitam Horm. 2016;102:227–249.
   PubMed Web of Science ®Google Scholar
• Pipes GT, Yang J. Cardioprotection by thymosin beta 4. Vitam Horm. 2016;102:209–226.
   PubMed Web of Science ®Google Scholar
• Sosne G, Rimmer D, Kleinman HK, et al. Thymosin beta 4: a potential novel therapy for neurotrophic keratopathy, dry eye, and ocular surface diseases. Vitam Horm. 2016;102:277–306.
   PubMed Web of Science ®Google Scholar
• Crockford D, Turjman N, Allan C, et al. Thymosin beta 4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179–189.
   PubMed Web of Science ®Google Scholar
• Franco FJ, Diaz C, Barcia M, et al. Thymosin alpha 1 is anative peptide in several tissues. Biochim Biophys Acta. 1992;1120:43–48.
   PubMed Web of Science ®Google Scholar
• Chen JM, Dando PM, Rawlings ND, et al. Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem. 1997;272:8090–8098.
   PubMed Web of Science ®Google Scholar
• Sarandeses CS, Covelo G, Díaz-Jullien C, et al. Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase. J Biol Chem. 2003;278:13286–13293.
   PubMed Web of Science ®Google Scholar
• Manrow RE, Sburlati AR, Hanover JA, et al. Nuclear targeting of prothymosin alpha. J Biol Chem. 1991;266:3916–3924.
   PubMed Web of Science ®Google Scholar
• Eschenfeldt WH, Manrow RE, Krug MS, et al. Isolation and partial sequencing of the human prothymosin alpha gene family. Evidence against export of the gene products. J Biol Chem. 1989;264:7546–7555.
   PubMed Web of Science ®Google Scholar
• Iino S, Toyota J, Kumada H, et al. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. J Viral Hepat. 2005;12:300–306.
   PubMed Web of Science ®Google Scholar
• You J, Zhuang L, Cheng HY, et al. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: A randomized controlled study. World J Gastroenteroly. 2006;12:6715–6721.
   PubMed Web of Science ®Google Scholar
• Andreone P, Gramenzi A, Cursaro C, et al. In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. J Viral Hepat. 2001;8:194–201.
   PubMed Web of Science ®Google Scholar
• Kullavanuaya P, Treeprasertsuk S, Thong-Ngam D, et al. The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results. J Med Assoc Thai. 2001;84:462–468.
   Google Scholar
• Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9:593–608.
   PubMed Web of Science ®Google Scholar
• Billich A. Thymosin alpha1 SciClone pharmaceuticals. Curr Opin Investig Drugs. 2002;3:698–707.
   PubMedGoogle Scholar
• Carraro G, Naso A, Montomoli E, et al. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. Vaccine. 2012;30:1170–1180.
   PubMed Web of Science ®Google Scholar
• Maio M, Mackiewicz A, Testori A, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol. 2010;28:1780–1787.
   PubMed Web of Science ®Google Scholar
• Romani L, Moretti S, Fallarino F, et al. Jack of all trades: thymosin a1 and its pleiotropy. Ann N Y Acad Sci. 2012;1269:1–6. Approach to differences and complementarities of the therapies based on Tα1.
   PubMed Web of Science ®Google Scholar
• Garaci E, Pica F, Serafino A, et al. Thymosin a1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci. 2012;1269:26–33. The approach to the therapies of tumors based on Tα1.
   PubMed Web of Science ®Google Scholar
• Serafino A, Pica F, Andreola F, et al. Thymosin α1 activates complement receptor-mediated phagocytosis in human monocyte-derived macrophages. J Innate Immun. 2014;6(1):72–88.
   PubMed Web of Science ®Google Scholar
• Giuliani C, Napolitano G, Mastino A, et al. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol. 2000;30:778–786.
   PubMed Web of Science ®Google Scholar
• Knutsen AP, Freeman JJ, Mueller KR, et al. Thymosin-alpha1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model. Int J Immunopharmacol. 1999;21:15–26.
   PubMed Web of Science ®Google Scholar
• Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103:4232–4239.
   PubMed Web of Science ®Google Scholar
• Zhang P, Chan J, Dragoi AM, et al. Activation of IKK by thymosin α1 requires the TRAF6 signaling pathway. EMBO Rep. 2005;6:531–537.
   PubMed Web of Science ®Google Scholar
• Lao X, Liu M, Chen J, et al. A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1. PLoS One. 2013;8:e72242.
   PubMed Web of Science ®Google Scholar
• Zetter BR. On target with tumor blood vessel markers. Nat Biotechnol. 1997;15:1243–1244.
   PubMed Web of Science ®Google Scholar
• Leichtling KD, Serrate SA, Sztein MB. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol. 1990;12:19–29.
   PubMed Web of Science ®Google Scholar
• Romani L, Oikonomou V, Moretti S, et al. Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nat Med. 2017;23:590–600.
   PubMed Web of Science ®Google Scholar
• Grottesi A, Sette M, Palamara AT, et al. The conformation of peptide thymosin α1 in solution and in a membrane-like environment by circular dichroism and NMR spectroscopy. a possible model for its interaction with the lymphocyte membrane. Peptides. 1998;19:1731–1738.
   PubMed Web of Science ®Google Scholar
• Elizondo-Riojas MA, Chamow SM, Tuthill CW, et al. NMR structure of human thymosin alpha-1. Biochem Biophys Res Commun. 2011;416:356–361.
   PubMed Web of Science ®Google Scholar
• Tulumello DV, Deber CM. SDS Micelles as a membrane-mimetic environment for transmembrane segments. Biochemistry. 2009;48:12096–12103.
   PubMed Web of Science ®Google Scholar
• Nepravishta R, Mandaliti W, Eliseo T, et al. Thymosin α1 inserts N terminus into model membranes assuming a helical conformation. Expert Opin Biol Ther. 2015;15:S71–S81.
   PubMed Web of Science ®Google Scholar
• Sargent DF, Schwyzer R. Membrane lipid phase as catalyst for peptide receptor interactions. Proc Nat Acad Sci. 1986;83:5774–5778.
   PubMed Web of Science ®Google Scholar
• Mandaliti W, Nepravishta R, Sinibaldi Vallebona P, et al. New studies about the insertion mechanism of Thymosin α1 in negative regions of model membranes as starting point of the bioactivity. Amino Acids. 2016;48:1231–1239.
   PubMed Web of Science ®Google Scholar
• Mandaliti W, Nepravishta R, Sinibaldi Vallebona P, et al. Thymosin α1 interacts with exposed phosphatidylserine in membrane models and in cells and uses serum albumin as a carrier. Biochemistry. 2016;55:1462–1472.
   PubMed Web of Science ®Google Scholar
• Nepravishta R, Mandaliti W, Sinibaldi Vallebona P, et al. Mechanism of action of thymosin α1: does it interact with membrane by recognition of exposed phosphatidylserine on cell surface? A structural approach. Vitam Horm. 2016;102:101–119.
   PubMed Web of Science ®Google Scholar
• Xiu-Li A, Takakuwa Y, Manno S, et al. Structural and functional characterization of protein 4.1R-Phosphatidylserine interaction potential role in 4.1r sorting within cells. J Biol Chem. 2001;276:35778–35785.
   PubMed Web of Science ®Google Scholar
• Lee G, Pollard HB, Arispe N. Annexin 5 and apolipoprotein E2 protect against Alzheimer’s amyloid-β-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides. 2002;23:1249−1263.
   PubMed Web of Science ®Google Scholar
• van Engeland M, Nieland LJW, Ramaekers FCS, et al. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry. 1998;31:1−9.
   PubMedGoogle Scholar
• Denisov G, Wanaski S, Luan P, et al. Binding of basic peptides to membranes produces lateral domains enriched in the acidic lipids phosphatidylserine and phosphatidylinositol 4,5-bisphosphate: an electrostatic model and experimental results. Biophys J. 1998;74:731−744.
   PubMed Web of Science ®Google Scholar
• Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res. 2003;42:423−438.
   PubMed Web of Science ®Google Scholar
• Ortel TL, Devore-Carter D, Quinn-Allen MA, et al. Evidence for a phosphatidylserine binding site in factor v; the second c-type domain. J Biol Chem. 1992;267:4189−4198.
   PubMedGoogle Scholar
• Sun GY, Sun AY. Chronic ethanol administration induced an increase in phosphatidylserine in guinea pig synaptic plasma membranes. Biochem Biophys Res Commun. 1983;113:262−268.
   PubMed Web of Science ®Google Scholar
• Freikman I, Amer J, Cohen JS, et al. Oxidative stress causes membrane phospholipid rearrangement and shedding from RBC membranes, an NMR study. Biochim Biophys Acta, Biomembr. 2008;1778:2388−2394.
   PubMed Web of Science ®Google Scholar
• Lemmon MA. Engulfment of apoptotic cells involves Membrane recognition by phospholipid-binding domains. Nat Cell Biol. 2008;1:456−461.
   Google Scholar
• Verhoven B, Schlegel RA, Williamson P. Mechanisms of Phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T Lymphocytes. J Exp Med. 1995;182:1597−1601.
   PubMed Web of Science ®Google Scholar
• Mariño G, Kroemer G. Mechanisms of apoptotic phosphatidylserine exposure. Cell Res. 2013;23:1247−1248.
   PubMed Web of Science ®Google Scholar
• Maler L. Solution NMR studies of cell-penetrating peptides in model membrane systems. Adv Drug Delivery Rev. 2013;65:1002−1011.
   PubMed Web of Science ®Google Scholar
• Castanho MA, Fernandes MX. Lipid membrane induced optimization for ligand−receptor docking: recent tools and insights for the “membrane catalysis” model. Eur Biophys J. 2006;35:92− 103.
   PubMed Web of Science ®Google Scholar
• Vauquelin G, Packeu A. Ligands, their receptors and plasma membranes Review. Mol Cell Endocrinol. 2009;311:1−10.
   PubMed Web of Science ®Google Scholar
• MäLer L. Solution NMR studies of peptide-lipid interactions in model membranes. Mol Membr Biol. 2012;29:155−176.
   PubMed Web of Science ®Google Scholar
• Ying J, Ahn J-M, Jacobsen NE, et al. NMR solution structure of the glucagon antagonist(desHis1, desPhe6, Glu9)glucagon amide in the presence of perdeuterated dodecylphosphocholine micelles. Biochem. 2003;42:2825−2835.
   PubMed Web of Science ®Google Scholar
• Langelaan DN, Rainey JK. Membrane catalysis of peptide−receptor binding. Biochem Cell Biol. 2010;88:203−210.
   PubMed Web of Science ®Google Scholar
• Pliska V, Folkers G, Spiwok V. Thermodynamics of the interaction between oxytocin and its myometrial receptor in sheep: A stepwise binding mechanism. Biochem Pharmacol. 2014;91:119−127.
   PubMed Web of Science ®Google Scholar
• Iłowska E, Wyrzykowski D, Kwiatkowska A, et al. Membrane structure and interactions of peptide hormones with model lipid bilayers. Biochim Biophys Acta, Biomembr. 2012;1818:2982−2993.
   PubMed Web of Science ®Google Scholar
• Staes E, Absil P-A, Lins L, et al. Acylated and unacylated ghrelin binding to membranes and to ghrelin receptor: towards a better understanding of the underlying mechanisms. Biochim Biophys Acta, Biomembr. 2010;1798:2102−2113.
   PubMed Web of Science ®Google Scholar
• Pedersen SL, Bhatia VK, Jurt S, et al. Improving membrane binding as a design strategy for amphipathic peptide hormones: 2-helix variants of PYY3−36. J Pept Sci. 2012;18:579−587.
   PubMed Web of Science ®Google Scholar
• Machuqueiro M, Campos SRR, Soares CM, et al. Membrane-induced conformational changes of kyotorphin revealed by molecular dynamics simulations. J Phys Chem, B. 2010;114:11659−11667.
   PubMed Web of Science ®Google Scholar
• Chartrand E, Arnold AA, Gravel A, et al. Potential role of the membrane in hERG channel functioning and drug-induced long QT syndrome. Biochim Biophys Acta, Biomembr. 2010;1798:1651−1662.
   PubMed Web of Science ®Google Scholar
• Langelaan DN, Rainey JK. Headgroup-Dependent membrane catalysis of Apelin-Receptor interactions is likely. J Phys Chem B. 2009;113:10465−10471.
   PubMed Web of Science ®Google Scholar
• Myers GA, Gacek DA, Peterson EM, et al. Microscopic rates of peptide−phospholipid bilayer interactions from single-molecule residence times. J Am Chem Soc. 2012;134:19652−19660.
   PubMed Web of Science ®Google Scholar
• Veiga AS, Santos NC, Loura LM, et al. HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency. J Am Chem Soc. 2004;126:14758−14763.
   PubMed Web of Science ®Google Scholar
• Veiga S, Henriques VS, Santos N, et al. M Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level. Biochem J. 2004;377:107−110.
   PubMed Web of Science ®Google Scholar
• Wang D, Gou S-Y, Axelrod D Jr. Reaction rate enhancement by surface diffusion of adsorbates. Biophys Chem. 1992;43:117−137.
   PubMed Web of Science ®Google Scholar
• Axelrod D, Wang MD. Reduction-of- dimensionality kinetics at reaction-limited cell surface receptors. Biophys J. 1994;66:588−600.
   PubMed Web of Science ®Google Scholar
• Lesovoy DM, Bocharov EV, Lyukmanova EN, et al. Specific membrane binding of Neurotoxin II can facilitate its delivery to acetylcholine receptor. Biophys J. 2009;97:2089−2097.
   PubMed Web of Science ®Google Scholar
• Vauquelin G. Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin. Drug Discovery. 2010;5:927−941.
   PubMed Web of Science ®Google Scholar
• Sykes DA, Parry C, Reilly J, et al. Observed drug-receptor association rates are governed by membrane affinity: the importance of establishing ″micropharmacokinetic/pharmacodynamic relationships″ at the β2-adrenoceptor. Mol Pharmacol. 2014;85:608−617.
   PubMed Web of Science ®Google Scholar
• daCosta CJB, Wagg ID, McKay M, et al. Phosphatidic acid and phosphatidylserine have distinct structural and functional interactions with the nicotinic acetylcholine receptor. J Biol Chem. 2004;279:14967−14974.
   PubMed Web of Science ®Google Scholar
• Lee YS, Muthu D, Hall SM, et al. Discovery of amphipathic dynorphin a analogues to inhibit the neuroexcitatory effects of dynorphin a through bradykinin receptors in the spinal cord. J Am Chem Soc. 2014;136:6608−6616.
   PubMed Web of Science ®Google Scholar
• Dennis MS, Zhang M, Meng YG, et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem. 2002;277:35035−35043.
   PubMed Web of Science ®Google Scholar
• Kurtzhals P, Havelund S, Jonassen I, et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J. 1995;312:725−731.
   PubMed Web of Science ®Google Scholar
• Markussen J, Havelund S, Kurtzhals P, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia. 1996;39:281−288.
   PubMed Web of Science ®Google Scholar
• Gordon LM, Curtai CC, McCloyn V, et al. The amino-terminal peptide of HIV-1 gp41 interacts with human serum albumin. AIDS Res Hum Retroviruses. 1993;9:1145−1156.
   PubMed Web of Science ®Google Scholar
• Tritsch GL. Localized conformational perturbation of human serum albumin. a study of the thyroxine binding site at the amino terminus’. Arch Biochem Biophys. 1968;127:384−390.
   PubMed Web of Science ®Google Scholar
• Jian-Hua C, Zhang X-G, Jiang Y-T, et al. Bioactivity and pharmacokinetics of two human serum albumin–thymosin _1-fusion proteins, rHSA-T_1 and rHSA-L-T_1, expressed in recombinant Pichia pastoris. Cancer Immunol Immunother. 2010;59:1335–1345.
   PubMed Web of Science ®Google Scholar
• Frey S, Tamm LK. Membrane insertion and lateral diffusion of fluorescence-labelled cytochrome c oxidase subunit IV signal peptide in charged and uncharged phospholipid bilayers. Biochem J. 1990;272:713–719.
   PubMed Web of Science ®Google Scholar
• Ramadurai S, Holt A, Krasnikov V, et al. Lateral diffusion of membrane proteins. J Am Chem Soc. 2009;131:12650–12656.
   PubMed Web of Science ®Google Scholar
• De Laat W, Van Der Saag PT, Elsont EL, et al. Lateral diffusion of membrane lipids and proteins during the cell cycle of neuroblastoma cells. Proc Natl Acad Sci USA. 1980;77:1526–1528.
   PubMed Web of Science ®Google Scholar
• Gavutis M, Lata S, Lamken P, et al. Lateral ligand-receptor interactions on membranes probed by simultaneous fluorescence-interference detection. Biophysical Journal. 2005;88:4289–4302.
   PubMed Web of Science ®Google Scholar
• Mandaliti W, Nepravishta R, Pica F, et al. Thymosin α1 interacts with hyaluronic acid electrostatically by its terminal sequence LKEKK. Molecules. 2017;22(molecules):22111843.
   Google Scholar
• Stoll R, Voelter W, Holak TA. Conformation of thymosin beta 9 in water/fluoroalcohol solution determined by NMR spectroscopy. Biopolymers. 1997;41:623–634.
   PubMed Web of Science ®Google Scholar
• Zarbock J, Oschkinat H, Hannappel E, et al. Solution conformation of thymosin beta 4: a nuclear magnetic resonance and simulated annealing study. Biochemistry. 1990;29:7814–7821.
   PubMed Web of Science ®Google Scholar
• Czisch M, Schleicher M, Hörger S, et al. Conformation of thymosin beta 4 in water determined by NMR spectroscopy. Eur J Biochem. 1993;218:335–344.
   PubMedGoogle Scholar
• Safer D, Chowrashi PK. Beta-thymosins from marine invertebrates: primary structure and interaction with actin. Cell Motil Cytoskeleton. 1997;38:163–171.
   PubMed Web of Science ®Google Scholar
• Xue B, Robinson RC. Actin-induced structure in the beta-thymosin family of intrinsically disordered proteins. Vitam Horm. 2016;102:55–71.
   PubMed Web of Science ®Google Scholar
• Dominguez R. The beta-thymosin/WH2 fold: multifunctionality and structure. Ann N Y Acad Sci. 2007;1112:86–94.
   PubMed Web of Science ®Google Scholar
• Aguda AH, Xue B, Irobi E, et al. The structural basis of actin interaction with multiple WH2/beta-thymosin motif-containing proteins. Structure. 2006;14:469–476.
   PubMed Web of Science ®Google Scholar
• Irobi E, Aguda AH, Larsson M, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. Embo J. 2004;23:3599–3608.
   PubMed Web of Science ®Google Scholar
• Domanski M, Hertzog M, Coutant J, et al. Coupling of folding and binding of thymosin beta4 upon interaction with monomericm actin monitored by nuclear magnetic resonance. J Biol Chem. 2004;279:23637–23645.
   PubMed Web of Science ®Google Scholar
• 5th Tymosins Meeting. Washington DC: Abstract book; 2017.
   Google Scholar